Prescient Therapeutics Ltd. said the U.S. Food and Drug Administration lifted the clinical hold on the company's trial for PTX-200 in patients with breast cancer.
The company will resume the study in HER2 negative breast cancer patients, the last of three PTX-200 trials paused in May following the death of a patient who experienced liver failure.
The regulator lifted the clinical hold after the company met certain of its guidelines.
The PTX-200 trial for breast cancer will now move on to a phase 2 study. Prior to the hold, the drug cleared a phase 1b study for the same indication.
The U.S. FDA earlier lifted the hold on trials for PTX-200 in patients with acute myeloid leukemia and ovarian cancer.
